How is the Polynovo share price managing to push higher today?

Polynovo shares are defying the broader ASX market on Thursday.

| More on:
Team celebrating corporate success screaming with joy.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Polynovo shares are outperforming the broader market, currently up 4%
  • The company's chair, David Williams, has picked up another batch of shares
  • It appears Williams, among other insiders, believes that Polynovo shares are currently undervalued

In a sea of red across the ASX today, the Polynovo Ltd (ASX: PNV) share price is hovering in positive territory.

During the first hour of trade, the medical device company's shares soared to an intraday high of $1.34.

However, they have retraced a touch to $1.285, a 4.05% gain on yesterday's closing price.

In comparison, the All Ordinaries Index (ASX: XAO) is 1.44% in the red in what has become another volatile day.

Polynovo chair seizes buying opportunity

Taking advantage of the recent Polynovo share price weakness, the company's chair David Williams has picked up more shares.

According to a company release, Williams has bought 346,193 shares at an average price of $1.2431 apiece. This was conducted via an on-market trade by Williams' subsidiary, Lawn Views Pty Ltd.

The transaction equated to a value of more than $430,300.

Following the latest purchase, Williams now has more than 22.25 million fully paid ordinary Polynovo shares across all holdings.

The latest buy-in could reflect that Williams believes Polynovo shares are trading at bargain levels.

It is worth noting that at the beginning of May, Polynovo shares touched a 52-week low of 83.5 cents. Since then, a number of directors, particularly Williams, have made a series of purchases.

Polynovo share price summary

Despite this month's 15% gain, Polynovo shares have fallen by almost 50% in the past 12 months.

Although, when looking at the year to date, its shares are down around 18%.

Based on today's price, Polynovo presides a market capitalisation of roughly $856.89 million.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended POLYNOVO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.
Healthcare Shares

This ASX All Ords share is diving 18% as inflation pain draws blood

This healthcare company delivered a trading update at its annual general meeting today.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

Up 427% this year, why today is a big day for Mesoblast shares

Why is everyone talking about Mesoblast shares on Friday?

Read more »

A man holds his hand under his chin as he concentrates on his laptop screen and reads about the ANZ share price
Healthcare Shares

Is this beaten-down ASX healthcare share a bargain buy now?

One expert has given their view on this stock.

Read more »

drug capsule opening up to reveal dollar signs signifying rising asx share price
Healthcare Shares

3 ASX healthcare shares going gangbusters on Thursday

Investors are sending these ASX healthcare stocks soaring today. But why?

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Is it time to cash in on Sigma shares?

Shares have extended after the Chemist Warehouse merger.

Read more »

Person holding Australian dollar notes, symbolising dividends.
Healthcare Shares

Buy this ASX 200 share that is swimming in cash

Bell Potter sees potentially big returns on offer from this cashed-up stock.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Are CSL shares a buy after the biotech's FY25 forecasts?

Brokers continue to weigh in.

Read more »

Female pharmacist smiles with a digital tablet.
Healthcare Shares

Are Wesfarmers or Sigma shares a better buy in the pharmacy arena?

These two stocks are both leaders in the industry.

Read more »